Stony Brook, Dexcom Fight Blood Sugar Crises In Coronavirus Patients With New Monitoring System
STONY BROOK, NY, APRIL 17, 2020— As Coronavirus symptoms impact everyone differently, it seems to have a significant impact on blood sugar, whether a patient is a known diabetic or not. To be able to give patients the best form of treatment, Stony Brook Medicine is working with Dexcom, a company that develops, manufactures, and distributes continuous glucose monitoring systems, to streamline the treatment process.
"COVID-19 has profound and unprecedented impact on glycemic control in patients both with and without a known history of diabetes," said Joshua Miller, MD, MPH, Medical Director of Diabetes Care at Stony Brook Medicine and Assistant Professor of Medicine, Endocrinology and Metabolism at Renaissance School of Medicine at Stony Brook University.
The Stony Brook Medicine Diabetes Program is now modifying its reporting platform to monitor and recognize patients with COVID-19 who may also be suffering from a blood sugar crisis. Dexcom has manufactured 100,000 CGM instruments, a small wearable sensor that monitors the glucose level of a patient, to be used on patients suffering from Coronavirus, allowing healthcare workers to monitor the glucose levels of in-patients remotely.
The system provides real-time monitoring numbers through the use of a phone and a receiver, allowing for less interaction between healthcare workers and COVID-19 patients, limiting viral exposure and saving PPE usage. Dexcom has received FDA approval on the CGM tools.